Guggenheim analyst Seamus Fernandez raised the firm’s price target on Novo Nordisk to DKK 1,152 from DKK 1,081 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- Aeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- Novo Nordisk reports PIONEER PLUS trial achieved primary endpoint
- Novo Nordisk Drops Its Insulin Prices